LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
121.53
-0.17 (-0.14%)
At close: 4:03PM EST
Stock chart is not supported by your current browser
Previous Close121.70
Open121.98
Bid121.50 x 900
Ask121.52 x 1000
Day's Range120.72 - 122.19
52 Week Range101.36 - 132.13
Volume3199020
Avg. Volume3,073,011
Market Cap117B
Beta (5Y Monthly)0.17
PE Ratio (TTM)14.72
EPS (TTM)8.26
Earnings DateJan 30, 2020
Forward Dividend & Yield2.58 (2.12%)
Ex-Dividend Date2019-11-14
1y Target Est124.08
  • Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
    Zacks

    Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

    This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion

  • Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
    PR Newswire

    Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

    Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance® (empagliflozin) in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In both trials, there was no significant change from baseline to week 12 in exercise ability with Jardiance versus placebo, as measured by the six-minute walk test, which was the primary endpoint of the studies. The safety profile seen in the EMPERIAL trials was similar to the currently known safety profile of Jardiance and no new safety risks were identified.

  • CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
    PR Newswire

    CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

    Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending a new indication and associated label update for CYRAMZA® (ramucirumab). The Committee agreed that the label should include an indication for CYRAMZA in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. The CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the European Union.

  • Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor
    Zacks

    Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor

    Lilly (LLY) initiates a phase III study on its oral RET inhibitor, selpercatinib, in treatment-naive, RET fusion-positive NSCLC patients.

  • Barrons.com

    Big Pharma’s Coming Back in 2020. Don’t Hold Your Breath for Generic Drug Stocks

    The stocks of big pharmaceutical companies have trailed behind the market in 2019, despite a rally late in the year rally. But things are looking up, according to J.P. Morgan.

  • Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
    PR Newswire

    Lilly Opens First Ever Randomized Phase 3 Clinical Trial in Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer

    Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung cancer (NSCLC) patients. Enrolled trial participants will be randomized to receive either selpercatinib or platinum-based (carboplatin or cisplatin) and pemetrexed therapy with or without pembrolizumab as initial treatment of their advanced or metastatic RET fusion-positive NSCLC.

  • China’s Curing Cancer Faster and Cheaper Than Anywhere Else
    Bloomberg

    China’s Curing Cancer Faster and Cheaper Than Anywhere Else

    (Bloomberg) -- Zhang Haitao was a basketball-loving teenager who dreamed of going to a specialized sports high school when he got a pain in his right arm that just wouldn’t go away. It turned out to be acute lymphoblastic leukemia.The discovery set Zhang and his family, from a village deep in the mountains of southwestern China's Sichuan province, on a journey familiar to most cancer patients — a revolving door of hospital visits, blood tests and three rounds of chemotherapy. It was then that Zhang’s doctor suggested a last-ditch option: an experimental gene therapy being trialed by a Chinese startup called Gracell Biotechnology Ltd.After spending three weeks in the hospital in May — during which white blood cells were removed from his body, genetically engineered, and then infused back in — an analysis of Zhang’s bone marrow in June showed his body was clear of cancer.Seven months later, monthly medical tests conducted at a hospital in the nearby Chinese metropolis of Chongqing show he remains cancer free. “I don’t remember much about the treatment as I had a fever throughout,” said Zhang, who’s now almost 16 and spends his days playing video games and texting his friends. “It seems like a new solution that will give people hope.”Read more about how China is overhauling its healthcare systemThe therapy Zhang received was Chimeric Antigen Receptor-T cells, known as CAR-T, and it’s being hailed as one of the most exciting developments in the quest to cure cancer. First developed by Israeli scientist Zelig Eshhar in the 1980s, CAR-T re-works the genes of the body’s own immune cells so that they actively seek out and destroy cancer cells. While it’s been embraced by researchers and drugmakers around the world, perhaps nowhere is CAR-T having more impact — and being pushed dangerously close to its limits — than in China, home to the world’s biggest cancer population and some of the most ambitious experiments.CAR-T works by supercharging T-cells, the body’s main line of defense against disease, so that they latch onto and destroy cancer. In clinical trials, leukemia patients who failed to respond to other therapies have shown remission rates of over 90% within two months of treatment.Though drug giants Novartis AG and Gilead Sciences Inc. have been marketing CAR-T globally since 2017, it’s expensive. The process of engineering an individual’s cells in a laboratory and then replicating them has also meant that some patients with more aggressive cancers can die waiting for treatment.That’s where Gracell’s therapy was revolutionary. Instead of the two to three weeks taken by current treatments from American and European drug makers, the Shanghai-based company — set up by a group of veteran Chinese cell-therapy researchers — is churning out cancer-killing immune cells overnight.And they’re doing it much cheaper in some cases than global pharmaceutical giants. Gracell has developed a process using genetic engineering that speeds up the cell production stage, according to founder William Cao Wei. Gracell plans to price its CAR-T treatment for about 500,000 yuan ($71,000), well below the $475,000 price tag for Novartis’ Kymriah, the Swiss company’s CAR-T therapy used to treat the type of blood cancer that Zhang had. A similar treatment from Gilead, based in Foster City, California, costs $373,000.The aging population and a raft of lifestyle factors mean that more new cancer patients are emerging in China than anyplace else in the world, giving the country a significant stake in the global fight to find a cure. Emboldened by the government’s push to become a scientific superpower and to dominate the field of genetics, Gracell and other Chinese biotech startups are racing ahead, with China likely to approve CAR-T for widespread use as early as next year. Up for grabs is a market for cancer drugs and experimental treatments that has exploded to $133 billion a year worldwide, according to life sciences researcher Iqvia Institute.“There can be both cooperation and competition between us and CAR-T developers in developed markets,” said Cao, who is also Gracell’s chief executive officer. “But there will definitely be competition.” That drive to forge ahead — and in front — can be seen in the way China is approaching regulation of CAR-T. The country is weighing new rules that would loosen oversight of the revolutionary technology, allowing academic ethics committees within hospitals to approve new CAR-T treatments and then administer them to patients for a fee.That would markedly loosen China’s current framework, which is presently in line with the approach taken by regulatory bodies like the U.S Food and Drug Administration and the European Medicines Agency. These entities are the sole authorities in their jurisdictions that evaluate and approve all CAR-T therapies before they are cleared for public use.There is concern among researchers, regulatory experts and drugmakers themselves that allowing hospitals to market treatments for a fee could cause profit-making to trump ethical considerations. In a 2016 case widely reported in the Chinese media, a 22-year-old college student with a rare type of tissue cancer called synovial sarcoma died after going through an experimental cell therapy at a Beijing hospital.“Hospitals can become both players and referees at the same time”Before his death, the patient posted an essay online claiming the hospital had falsely advertised the treatment’s effectiveness, and that Chinese search engine Baidu Inc. had displayed the hospital’s advertising so that it appeared like a credible search result rather than a paid commercial. The essay went viral and sparked an outcry on Chinese social media over the ethics of private hospitals and the regulation of therapies for serious illnesses.Censured by the Cyberspace Administration of China, Baidu responded by restricting the number of sponsored posts to 30% of a results page, and established a 1 billion yuan fund to fight fraud. The hospital did not respond to requests for comment.It’s not the only death allegedly linked to genetic cell therapy in China. Last year, a hospital in the eastern city of Xuzhou was sued over the death of a lymphoma patient who died after receiving a CAR-T treatment. The patient developed severe side effects, including bleeding within the abdomen. The patient’s family argued that the treatment led to his death, but the hospital and doctor said it was the result of late-stage cancer. A court is yet to rule on the case.China’s proposed new framework is reminiscent of its wider approach to the regulation of science, an area President Xi Jinping has prioritized as part of his ambition to cement the country as a world power.The research of He Jiankui, an American-educated Chinese scientist whose revelation last year that he’d edited the genes of twin baby girls ignited a global firestorm, was signed off by the ethics committee of a Shenzhen hospital. The experiment, which He claimed made the twins immune to HIV, wasn’t backed by peer-reviewed data and still hasn’t been verified. Scientists around the world have condemned it as an irresponsible use of a technology that has the capacity to alter the very building blocks of life. The long-term effects of Crispr, the gene-snipping tool used by He and embraced by Chinese researchers, are also yet to be fully understood.China’s new draft rules on CAR-T could give rise to the same scenario, critics say.There’s no guarantee that the hospital committees have the qualifications to evaluate such a complicated therapy, said Tao Xin, a Washington, D.C.-based lawyer at Hogan Lovells LLP who specializes in the health-care regulatory law of both the U.S. and China.“The proposal indicates that hospitals can charge a fee for the therapy, in addition to approving its own therapy,” he said. “With these two combined, are we going to see a replay of the 2016 incident? If there’s money to be made and I get to decide whether to do it or not, that’s really controversial.”Read about how Crispr is being used in China’s quest to make a super pigGracell’s Cao is also critical of the new framework as it removes the role of an independent entity that evaluates the therapy’s safety and efficacy: “Hospitals can become both players and referees at the same time.”Novartis and Gilead declined to comment on China’s regulatory plans, while a spokesman for the National Health Commission, the body in charge of governing the country’s health sector, said that the proposed new rules are still under discussion.Read about how Chinese parents are using DNA tests to map out their children’s livesMeanwhile, Chinese companies are racing ahead on CAR-T and attracting hundreds of millions of dollars from investors like Singapore’s sovereign wealth fund Temasek Holdings Pte Ltd, as well as global pharmaceutical giants. Venture capital investment in Chinese biotech firms climbed to $17.6 billion last year, quadruple the amount from 2015, according to consultancy ChinaBio LLC. Gracell — which counts Temasek and Lilly Asia Ventures, the venture capital firm spun off from Eli Lilly & Co. as investors — says 32 of the 35 patients it’s enrolled in its China-based trials over the past year have gone into complete remission “with minimal residual disease tested negative” four weeks after the CAR-T infusion — a clinical term that basically means there was no evidence of disease remaining in their bodies, the highest possible efficacy level for a therapy.Other Chinese startups like Nanjing Legend, a unit of Hong Kong-listed Genscript Biotech Corp., and U.S.-listed Cellular Biomedicine Group Inc., have developed similar capabilities.In 2018, Novartis paid $40 million for a 9% stake in Shanghai-based Cellular Biomedicine, and will use their cell therapy facility to manufacture its Kymriah treatment, which is currently being assessed for approval by China’s drug regulator. The startup is also developing its own CAR-T therapies and testing their potential against solid tumors, not just blood cancers. Chief Executive Officer Tony Liu Bizuo said Cellular Biomedicine’s digitized and automated process cuts the cell engineering time from four weeks to less than 10 days.Cellular Biomedicine is now mulling building a bigger cell production facility with the Shanghai government, as demand for cell therapy grows and on expectations more commercial CAR-T treatments will be approved in China in the coming years. In a sign of the support startups are getting from the authorities, the city’s government has earmarked a 4 million square feet space for cell therapy research. Of the 21 cell therapies currently in clinical trials approved by China’s drug regulator, 11 are being conducted in the lab, which is fast becoming the nation’s CAR-T Ground Zero.The next frontier is to make CAR-T as accessible as any other drug, and Chinese startups are at the leading edge. Dubbed “universal CAR-T,” this involves finding a way to take T-cells from healthy people and engineering them so that they can be infused into any cancer patient. Gracell is studying the use of donor white blood cells, marking a step toward that goal. Other startups like French company Cellectis SA are also racing to make universal CAR-T a reality.“I’m very impressed with the pace of technological progress in China and the expansion of CAR-T research coming so rapidly,” said Bruce Levine, a professor specializing in cancer gene therapy at the Perelman School of Medicine at the University of Pennsylvania.“We all want these therapies to move fast and some are very good, but we need to be aware that some could be moving too fast for their expertise, even if they have very good intentions,“ he said.Read about how a Chinese genetics giant wants to tailor drugs to people’s DNAAfter a year in and out of hospital, Zhang, the teenage cancer patient in Chongqing, is starting to make plans for the future. If it wasn’t for the leukemia, he’d be in his first year of high school now.“I don’t think I can go to sports school anymore, but I hope to learn a professional skill,” said Zhang, who’s now a foot taller than his aunt, Chen Chunhua, his primary caregiver. “I want to grasp this chance I have.”While China’s approach to CAR-T may be criticized as moving too fast, Chen, who left her job at a ceramics factory to care for Zhang when he got sick, is thankful he had access to the treatment, which wouldn’t have been possible in China had the boy fallen ill just a year earlier.“I’m so happy we had this option within China,” she said. “It really helps to lessen our burden.”  \--With assistance from Dong Lyu.To contact the editor responsible for this story: Rachel Chang at wchang98@bloomberg.net, Anjali CordeiroFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • World's largest biotech company to move up to BioMed's big South City project
    American City Business Journals

    World's largest biotech company to move up to BioMed's big South City project

    The biotech company acquired its first Bay Area presence 15 years ago; now it's planning to move into a high-profile biotech-focused project.

  • Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
    PR Newswire

    Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting

    Eli Lilly and Company (NYSE: LLY) today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial. LOXO-305 is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. These data were presented today at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando (abstract 501). At all doses studied, LOXO-305 delivered objective responses in patients who had received diverse prior therapies and had exhibited varied molecular mechanisms of acquired resistance.

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Barrons.com

    Citigroup and 23 More Dividend Stocks That Offer Shelter in Today’s Economy

    Now that the U.S. economy is expanding less quickly, stocks with the fastest and most sustainable dividend growth are worth considering, according to a recent research note by UBS.

  • Lilly Announces New Leadership and Strategy in Oncology Research and Development
    PR Newswire

    Lilly Announces New Leadership and Strategy in Oncology Research and Development

    Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D;, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The new organization, named Loxo Oncology at Lilly, will be led jointly by Josh Bilenker, M.D., Jacob Van Naarden, and Nisha Nanda, Ph.D., and will report into Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. Lilly today also announced that David Hyman, M.D. will join the leadership team as chief medical officer of the new organization, beginning in January 2020. Dr. Hyman currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.

  • Reuters

    REFILE-Eli Lilly to put Loxo executives in charge of new cancer research unit

    U.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired earlier this year. The move highlights Lilly's efforts to double down on its cancer business following the $8 billion acquisition of Loxo in February. The company has been focused on increasing sales in core franchises, including diabetes and oncology, as sales of older blockbuster medicines such as diabetes treatment Humalog and erectile dysfunction drug Cialis face pressure from generic competition.

  • Here's Why I Think Eli Lilly (NYSE:LLY) Is An Interesting Stock
    Simply Wall St.

    Here's Why I Think Eli Lilly (NYSE:LLY) Is An Interesting Stock

    Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

  • Another Big Pharma jumps into biotech space race to snag Bay Area startups
    American City Business Journals

    Another Big Pharma jumps into biotech space race to snag Bay Area startups

    Eli Lilly's new space in South San Francisco could provide a home for 10-15 small-but-growing life sciences companies.

  • Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference
    PR Newswire

    Lilly to Participate in Evercore ISI 2nd Annual HealthCONx Conference

    Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:30 a.m., Eastern Time.

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    Pharmaceutical stocks rose a single-digit percentage in the first 11 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.

  • Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco
    PR Newswire

    Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco

    Eli Lilly and Company (NYSE: LLY) today unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.

  • Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)
    PR Newswire

    Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory Bowel Disease (IBD)

    Eli Lilly and Company's (NYSE: LLY) first digital health open innovation challenge, "Transforming IBD Care: Better Disease Monitoring, Management, and Care for People with Inflammatory Bowel Disease," has concluded, with HealthVoyager, an application developed by Boston Children's Hospital and Klick Health, being named the winner. The idea leverages a highly customizable software platform for doctors to create a personalized and immersive educational experience for patients living with inflammatory bowel disease (IBD). At Lilly's headquarters in Indianapolis, five finalists presented their digital health solutions aimed at transforming IBD care, during which an expert panel of judges evaluated each idea's impact, novelty, technical feasibility and ability to address long-term needs of people with IBD.

  • The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
    Zacks

    The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

    The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

  • Here is What Hedge Funds Think About Eli Lilly and Company (LLY)
    Insider Monkey

    Here is What Hedge Funds Think About Eli Lilly and Company (LLY)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 52% and 49% respectively. Hedge funds' top 3 stock picks returned 39.1% this year and beat the S&P […]

  • Top Research Reports for Merck, Eli Lilly & Charter Communications
    Zacks

    Top Research Reports for Merck, Eli Lilly & Charter Communications

    Top Research Reports for Merck, Eli Lilly & Charter Communications

  • Investing.com

    NewsBreak: Trump Looks to Let Florida, Others Import Prescription Drugs

    Investing.com – President Donald Trump tweeted on Friday the federal government is working on a plan to let Florida and other states import lower-priced prescription drugs for residents.

  • Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?
    Zacks

    Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?

    Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
    Zacks

    Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

    Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.